RXi Pharmaceuticals Corporation Stock Price, News & Analysis

RXII

Company Description

RXi Pharmaceuticals Corporation (Nasdaq: RXII) is a publicly traded company.

RXII stock has declined 42.1% over the past year.

This page provides a comprehensive overview of RXII stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

-42.07%

Performance 1 year

$0.0

Market Cap

0.0

Shares outstanding

RXi Pharmaceuticals Corporation (RXII) stock. Over the past 12 months, the stock has lost 42.1%.

Latest News

View All

March 25, 2021

—

Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update

earnings

March 11, 2021

—

Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting

conferences

March 1, 2021

—

Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies

clinical trial

February 12, 2021

—

Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market

offering

January 25, 2021

—

Phio Pharmaceuticals Announces Closing of $14.0 Million Private Placement Priced At-the-Market

private placement

November 10, 2020

—

Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update

earnings

RXi Pharmaceuticals Corporation has 6 recent news articles. Key topics include earnings, conferences, clinical trial, offering, private placement. View all RXII news →

SEC Filings

View All

No SEC filings available for RXII.

Financial Highlights

View Full Financials

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months